Stay updated with breaking news from Dose Escalation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An oral presentation titled "Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results"
- Enrollment progress update from ongoing China Phase 1 trial of TERN-701 to be presented at ASCO 2023 - China Phase 1 trial completed enrollment of Cohort 5 in the Dose Escalation phase FOSTER... | May 25, 2023
08.05.2023 - ─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for ...
Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) foll...
/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in...